Exelixis Inc (EXEL)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

1851 HARBOR BAY PARKWAY ALAMEDA, CA 94502

Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, it established a broad drug discovery and development platform that has served as the foundation for its continued efforts to bring new cancer therapies to patients in need. Its discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and it has entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from its marketed products and collaborations, it is committed to prudently reinvesting in its business to maximize the potential of its pipeline. It is supplementing its existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune's 100 Fastest-Growing Companies list for the first time, ranking 17th overall and the third-highest biopharmaceutical company.

Data as of 2021-06-19 11:15:07 -0400
Market Cap7.023 Billion Shares Outstanding313.387 Million Avg 30-day Volume1.543 Million
P/E Ratio108.42994 Dividend Yield EPS0.203
Price/Sales6.81 Debt to Equity1.15 EBITDA62.837 Million
Price to Book Value3.67 Forward PE66.51 Enterprise Value5.838 Billion
Total Cash1.185 Billion Current Debt213.337 Million Gross Profit990.672 Million
BETA0.85529 52-week High/Low27.35 / 18.18 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) 246.8588
Data provided by IEX Cloud
View SEC Filings from EXEL instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 4 4 0.0% 1 (0.06%) 2 (0.12%) -50.0%
Funds Holding: 336 345 -2.61% 79 (4.64%) 75 (4.35%) 5.33%
13F shares: 257.879 Million 260.225 Million -0.9% 63.706 Million 66.204 Million -3.77%
% Ownership 82.6563 83.8774 -1.46% 20.4193 21.3394 -4.31%
New Positions: 49 45 8.89% 21 13 61.54%
Increased Positions 109 131 -16.79% 24 35 -31.43%
Closed Positions 50 58 -13.79% 13 29 -55.17%
Reduced Positions 117 113 3.54% 28 24 16.67%
Total Calls 981.506 Thousand 884.458 Thousand 10.97% 267.4 Thousand 278.3 Thousand -3.92%
Total Puts 716.705 Thousand 1.363 Million -47.41% 174.6 Thousand 496.9 Thousand -64.86%
PUT/CALL Ratio 0.73 1.54 -52.6% 0.65 1.79 -63.69%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding EXEL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EXEL BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

360.1 Thousand total shares from 12 transactions

Exercise Derivative Conversion (M)

420 Thousand total shares from 8 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LAMB PETER EVP, SCIENTIFIC STRATEGY & CSO

  • Officer
521,572 2021-06-17 12

WILLSEY LANCE

  • Director
33,549 2021-05-27 3

WYSZOMIERSKI JACK L

  • Director
256,486 2021-05-27 3

COHEN CHARLES

  • Director
33,549 2021-05-27 3

FELDBAUM CARL B

  • Director
33,549 2021-05-27 2

GARBER ALAN M

  • Director
33,549 2021-05-27 2

MARCHESI VINCENT T

  • Director
91,012 2021-05-27 4

PAPADOPOULOS STELIOS

  • Director
1,304,551 2021-05-27 2

POSTE GEORGE

  • Director
173,614 2021-05-27 4

SMITH JULIE

  • Director
32,725 2021-05-27 1

FREIRE MARIA C

  • Director
56,724 2021-05-27 2

HALEY PATRICK J. EVP, COMMERCIAL

  • Officer
315,181 2021-05-15 10

SCHWAB GISELA PRES, PROD DEV & MED AFF & CMO

  • Officer
778,958 2021-05-13 10

MORRISSEY MICHAEL PRESIDENT AND CEO

  • Officer
  • Director
1,548,330 2021-05-12 9

HESSEKIEL JEFFREY EVP AND GENERAL COUNSEL

  • Officer
629,247 2021-04-26 12

SENNER CHRISTOPHER J. EVP AND CFO

  • Officer
359,314 2021-03-04 9

SCANGOS GEORGE A

  • Director
738,312 2020-05-18 0

BURKE DEBORAH SVP & CHIEF FINANCIAL OFFICER

  • Officer
19,990 2014-11-15 0

SIMONTON PAMELA A EVP, EXELIXIS

  • Officer
28,091 2014-02-15 0

KARBE FRANK EVP AND CFO

  • Officer
105,839 2014-02-15 0

MCCORMICK FRANK

  • Director
0 2013-12-06 0

GARLAND J. SCOTT EVP & CHIEF COMMERICAL OFFICER

  • Officer
0 2013-09-18 0

RIVERA LUPE M EVP, OPERATIONS

  • Officer
22,051 2011-08-15 0

HELLER FRANCES K EVP, BUSINESS DEVELOPMENT

  • Officer
17,254 2011-05-15 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

LAMB PETER - Officer EVP, SCIENTIFIC STRATEGY & CSO

2021-06-22 20:03:49 -0400 2021-06-17 M 60,000 $1.90 a 449,467 direct

LAMB PETER - Officer EVP, SCIENTIFIC STRATEGY & CSO

2021-06-22 20:03:49 -0400 2021-06-17 M 60,000 d 115,000 direct

LAMB PETER - Officer EVP, SCIENTIFIC STRATEGY & CSO

2021-06-22 20:03:49 -0400 2021-06-17 S 60,000 $22.18 d 389,467 direct yes

GARBER ALAN M - Director

2021-05-28 20:17:02 -0400 2021-05-27 A 33,549 a 33,549 direct

WILLSEY LANCE - Director

2021-05-28 20:32:58 -0400 2021-05-27 A 33,549 a 33,549 direct

MARCHESI VINCENT T - Director

2021-05-28 20:28:19 -0400 2021-05-27 A 16,598 a 16,598 direct

FREIRE MARIA C - Director

2021-05-28 20:21:51 -0400 2021-05-27 A 16,598 a 16,598 direct

POSTE GEORGE - Director

2021-05-28 20:13:06 -0400 2021-05-27 A 16,424 a 173,614 direct -2.4465 -2.9707 0.0 1 -3.626 5

WYSZOMIERSKI JACK L - Director

2021-05-28 20:38:01 -0400 2021-05-27 A 16,598 a 16,598 direct

FELDBAUM CARL B - Director

2021-05-28 20:35:17 -0400 2021-05-27 A 33,549 a 33,549 direct

MARCHESI VINCENT T - Director

2021-05-28 20:28:19 -0400 2021-05-27 A 8,299 a 74,414 direct -2.4465 -2.9707 0.0 1 -3.626 5

FREIRE MARIA C - Director

2021-05-28 20:21:51 -0400 2021-05-27 A 8,299 a 40,126 direct -2.4465 -2.9707 0.0 1 -3.626 5

SMITH JULIE - Director

2021-05-28 20:08:51 -0400 2021-05-27 A 16,424 a 32,725 direct -2.4465 -2.9707 0.0 1 -3.626 5

WYSZOMIERSKI JACK L - Director

2021-05-28 20:38:01 -0400 2021-05-27 A 8,299 a 239,888 direct -2.4465 -2.9707 0.0 1 -3.626 5

PAPADOPOULOS STELIOS - Director

2021-05-28 20:26:03 -0400 2021-05-27 A 16,424 a 1,304,551 direct -2.4465 -2.9707 0.0 1 -3.626 5

COHEN CHARLES - Director

2021-05-28 20:19:44 -0400 2021-05-27 A 33,549 a 33,549 direct

HALEY PATRICK J. - Officer EVP, COMMERCIAL

2021-05-18 20:13:28 -0400 2021-05-18 S 14,593 $24.73 d 280,994 direct 3.0932 -5.0847 3.6441 3 -5.2542 5

HALEY PATRICK J. - Officer EVP, COMMERCIAL

2021-05-18 20:13:28 -0400 2021-05-15 F 3,026 $25.56 d 295,587 direct 3.0932 -5.0847 3.6441 3 -5.2542 5

MARCHESI VINCENT T - Director

2021-05-17 20:13:22 -0400 2021-05-14 M 40,000 d 0 direct

POSTE GEORGE - Director

2021-05-17 20:11:54 -0400 2021-05-14 S 40,802 $24.97 d 157,190 direct -3.0403 -8.1348 0.493 4 -8.1348 6

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2021-05-14 20:51:11 -0400 2021-05-14 G 19,722 d 491,813 direct -3.5658 -6.1807 0.0 1 -6.4976 3

MARCHESI VINCENT T - Director

2021-05-17 20:13:22 -0400 2021-05-14 S 40,000 $25.04 d 66,115 direct -3.0403 -8.1348 0.493 4 -8.1348 6

MARCHESI VINCENT T - Director

2021-05-17 20:13:22 -0400 2021-05-14 M 40,000 $6.30 a 106,115 direct -3.0403 -8.1348 0.493 4 -8.1348 6

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO by trust

2021-05-14 20:51:11 -0400 2021-05-14 G 19,722 a 1,038,789 indirect -3.5658 -6.1807 0.0 1 -6.4976 3

SCHWAB GISELA - Officer PRES, PROD DEV & MED AFF & CMO

2021-05-14 20:35:07 -0400 2021-05-13 M 100,000 $1.90 a 714,078 direct -3.5658 -6.1807 0.0 1 -6.4976 3

SCHWAB GISELA - Officer PRES, PROD DEV & MED AFF & CMO

2021-05-14 20:35:07 -0400 2021-05-13 M 100,000 d 150,000 direct

SCHWAB GISELA - Officer PRES, PROD DEV & MED AFF & CMO

2021-05-14 20:35:07 -0400 2021-05-13 S 100,000 $25.38 d 614,078 direct yes -3.5658 -6.1807 0.0 1 -6.4976 3

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2021-05-14 20:51:11 -0400 2021-05-12 M 50,000 d 100,000 direct

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2021-05-14 20:51:11 -0400 2021-05-12 F 30,278 $25.16 d 511,535 direct -3.5658 -6.1807 0.0 1 -6.4976 3

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2021-05-14 20:51:11 -0400 2021-05-12 M 50,000 $4.20 a 541,813 direct -3.5658 -6.1807 0.0 1 -6.4976 3

PAPADOPOULOS STELIOS - Director

2021-05-13 20:32:31 -0400 2021-05-11 M 40,000 d 0 direct

PAPADOPOULOS STELIOS - Director

2021-05-13 20:32:31 -0400 2021-05-11 S 5,075 $25.00 d 1,253,600 direct -1.252 -4.3036 0.0 1 -7.6682 4

PAPADOPOULOS STELIOS - Director

2021-05-13 20:32:31 -0400 2021-05-11 M 40,000 $6.30 a 1,228,897 direct -1.252 -4.3036 0.0 1 -7.6682 4

PAPADOPOULOS STELIOS - Director

2021-05-13 20:32:31 -0400 2021-05-11 M 40,000 d 0 direct

PAPADOPOULOS STELIOS - Director

2021-05-13 20:32:31 -0400 2021-05-11 S 5,473 $25.01 d 1,288,127 direct -1.252 -4.3036 0.0 1 -7.6682 4

PAPADOPOULOS STELIOS - Director

2021-05-13 20:32:31 -0400 2021-05-11 M 40,000 $3.13 a 1,258,675 direct -1.252 -4.3036 0.0 1 -7.6682 4

FREIRE MARIA C - Director

2021-05-17 20:15:43 -0400 2021-05-11 S 8,275 $25.01 d 31,827 direct -3.0403 -8.1348 0.493 4 -8.1348 6

PAPADOPOULOS STELIOS - Director

2021-05-13 20:32:31 -0400 2021-05-11 M 40,000 d 0 direct

PAPADOPOULOS STELIOS - Director

2021-05-13 20:32:31 -0400 2021-05-11 M 40,000 $3.38 a 1,293,600 direct -1.252 -4.3036 0.0 1 -7.6682 4

PAPADOPOULOS STELIOS - Director

2021-05-13 20:32:31 -0400 2021-05-11 S 10,222 $24.95 d 1,218,675 direct -1.252 -4.3036 0.0 1 -7.6682 4

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO by trust

2021-05-14 20:51:11 -0400 2021-05-10 G 40,616 d 1,019,067 indirect -3.5658 -6.1807 0.0 1 -6.4976 3

HALEY PATRICK J. - Officer EVP, COMMERCIAL

2021-04-28 20:08:02 -0400 2021-04-26 S 7,665 $25.03 d 297,392 direct yes -0.2835 -5.9538 -6.9259 3.5237 12 -10.6521 27

SCHWAB GISELA - Officer PRES, PROD DEV & MED AFF & CMO

2021-04-28 20:10:23 -0400 2021-04-26 M 50,000 $1.70 a 663,482 direct -0.2835 -5.9538 -6.9259 3.5237 12 -10.6521 27

SCHWAB GISELA - Officer PRES, PROD DEV & MED AFF & CMO

2021-04-28 20:10:23 -0400 2021-04-26 M 50,000 d 0 direct

HESSEKIEL JEFFREY - Officer EVP AND GENERAL COUNSEL

2021-04-28 20:06:49 -0400 2021-04-26 S 18,000 $25.03 d 628,248 direct yes -0.2835 -5.9538 -6.9259 3.5237 12 -10.6521 27

SCHWAB GISELA - Officer PRES, PROD DEV & MED AFF & CMO

2021-04-28 20:10:23 -0400 2021-04-26 S 50,000 $25.00 d 613,482 direct yes -0.2835 -5.9538 -6.9259 3.5237 12 -10.6521 27

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
EXELIXIS INC EXEL 2021-06-23 13:15:03 UTC -0.3606 0.4406 9100000
EXELIXIS INC EXEL 2021-06-23 12:45:03 UTC -0.3606 0.4406 9100000
EXELIXIS INC EXEL 2021-06-22 22:15:03 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 21:45:03 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 21:15:02 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 20:45:03 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 20:15:04 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 19:45:03 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 19:15:02 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 18:45:03 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 18:15:03 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 17:45:03 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 17:15:03 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 16:45:03 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 16:15:03 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 15:45:03 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 15:15:02 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 14:45:04 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 14:15:02 UTC -0.3606 0.4406 9500000
EXELIXIS INC EXEL 2021-06-22 13:45:03 UTC -0.3606 0.4406 9500000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Defensive Long Fund EXEL -162.0 shares, $-2789.64 2020-03-31 N-PORT
FundVantage Trust- Gotham Master Neutral Fund EXEL -90.0 shares, $-2200.5 2020-09-30 N-PORT
VANGUARD TRUSTEES' EQUITY FUND- VANGUARD ALTERNATIVE STRATEGIES FUND EXEL -8249.0 shares, $-183210.29 2021-01-31 N-PORT
FundVantage Trust- Gotham Hedged Plus Fund EXEL -1066.0 shares, $-24080.94 2021-03-31 N-PORT

Elevate your investments